Martin Braddock1. Show Affiliations » 1. AstraZeneca plc, Disease Science Section, Discovery Biosciences Division, Loughborough, Leicestershire, UK. martin.braddock@astrazeneca.com
Abstract
Entities: Disease
Mesh： See more » AnimalsAntibodies, Monoclonal/immunologyAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedCicatrix/drug therapyClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDrug Delivery Systems/methodsDrug Delivery Systems/trendsGenetic Therapy/methodsHumansInflammatory Bowel Diseases/drug therapyInflammatory Bowel Diseases/immunologyInfliximabIntegrin alpha4beta1/therapeutic useInterferon-gamma/therapeutic useNatalizumabNerve Growth Factor/geneticsNerve Growth Factor/therapeutic useRatsSheepStomach Ulcer/drug therapyStomach Ulcer/therapyWound Healing/drug effects
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedIntegrin alpha4beta1NatalizumabfontolizumabInterferon-gammaNerve Growth FactorInfliximabvisilizumab
Year: 2005 PMID： 15883915
Source DB: PubMed Journal: IDrugs ISSN： 1369-7056